COSCIENS Biopharma (CSCI) Competitors $3.40 +0.15 (+4.62%) (As of 11:36 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsSEC FilingsTrends CSCI vs. GANX, OSTX, RAPT, SCYX, BGM, VTVT, IMNN, IMMX, XLO, and VYNEShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Gain Therapeutics (GANX), OS Therapies (OSTX), RAPT Therapeutics (RAPT), SCYNEXIS (SCYX), Qilian International Holding Group (BGM), vTv Therapeutics (VTVT), Imunon (IMNN), Immix Biopharma (IMMX), Xilio Therapeutics (XLO), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical preparations" industry. COSCIENS Biopharma vs. Gain Therapeutics OS Therapies RAPT Therapeutics SCYNEXIS Qilian International Holding Group vTv Therapeutics Imunon Immix Biopharma Xilio Therapeutics VYNE Therapeutics Gain Therapeutics (NASDAQ:GANX) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends. Which has more risk & volatility, GANX or CSCI? Gain Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, COSCIENS Biopharma has a beta of 1.54, indicating that its stock price is 54% more volatile than the S&P 500. Which has stronger earnings & valuation, GANX or CSCI? COSCIENS Biopharma has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than COSCIENS Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K1,005.88-$22.27M-$1.30-1.52COSCIENS Biopharma$4.50M2.80-$16.55M-$11.87-0.29 Do analysts recommend GANX or CSCI? Gain Therapeutics presently has a consensus price target of $7.33, suggesting a potential upside of 272.25%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Gain Therapeutics is more favorable than COSCIENS Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00COSCIENS Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor GANX or CSCI? Gain Therapeutics received 31 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformGain TherapeuticsOutperform Votes3168.89% Underperform Votes1431.11% COSCIENS BiopharmaN/AN/A Do insiders and institutionals hold more shares of GANX or CSCI? 12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 0.7% of COSCIENS Biopharma shares are held by institutional investors. 11.7% of Gain Therapeutics shares are held by company insiders. Comparatively, 0.1% of COSCIENS Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is GANX or CSCI more profitable? Gain Therapeutics has a net margin of 0.00% compared to COSCIENS Biopharma's net margin of -428.43%. COSCIENS Biopharma's return on equity of -97.04% beat Gain Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -214.19% -129.96% COSCIENS Biopharma -428.43%-97.04%-46.86% Does the media favor GANX or CSCI? In the previous week, Gain Therapeutics and Gain Therapeutics both had 3 articles in the media. Gain Therapeutics' average media sentiment score of 0.67 beat COSCIENS Biopharma's score of 0.19 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive COSCIENS Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGain Therapeutics beats COSCIENS Biopharma on 10 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.58M$7.11B$5.33B$8.91BDividend YieldN/A8.03%4.98%4.03%P/E Ratio-0.2911.25135.4417.46Price / Sales2.80393.051,266.8895.47Price / CashN/A49.2238.8936.42Price / Book0.239.126.315.92Net Income-$16.55M$153.75M$118.33M$224.86M7 Day Performance-1.73%-1.20%-1.43%-0.38%1 Month Performance-9.57%8.48%3.12%4.21%1 Year PerformanceN/A39.61%36.57%27.31% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSCICOSCIENS BiopharmaN/A$3.40+4.6%N/AN/A$12.58M$4.50M-0.29N/AGap DownGANXGain Therapeutics2.969 of 5 stars$1.97-3.0%$7.33+272.3%-26.4%$50.29M$50,000.00-1.5220Short Interest ↑News CoverageOSTXOS TherapiesN/A$2.48-1.6%N/AN/A$49.72MN/A0.00N/APositive NewsGap UpRAPTRAPT Therapeutics4.5443 of 5 stars$1.38-12.1%$13.00+842.0%-87.0%$48.17M$1.53M-0.5080Analyst DowngradeAnalyst RevisionNews CoverageGap DownSCYXSCYNEXIS2.4841 of 5 stars$1.26-2.3%N/A-24.8%$47.82M$140.14M-1.7060Analyst RevisionPositive NewsBGMQilian International Holding GroupN/A$6.40-2.1%N/AN/A$46.27M$46.47M0.00298Positive NewsGap DownVTVTvTv Therapeutics0.5031 of 5 stars$15.20+2.0%N/A+4.6%$45.75M$1M-3.369News CoverageGap DownIMNNImunon3.0699 of 5 stars$0.76+1.8%$12.00+1,479.2%-24.2%$45.63M$500,000.00-0.4033Analyst ForecastShort Interest ↑Analyst RevisionGap UpIMMXImmix Biopharma3.1312 of 5 stars$1.61+2.9%$7.00+333.5%-63.1%$44.33MN/A-1.909Earnings ReportXLOXilio Therapeutics2.5234 of 5 stars$1.00+0.2%$4.00+300.0%-29.7%$43.96MN/A-0.5873Short Interest ↑VYNEVYNE Therapeutics2.5531 of 5 stars$2.97+2.1%$5.75+93.6%-16.4%$43.81M$420,000.00-3.4530Short Interest ↑ Related Companies and Tools Related Companies GANX Competitors OSTX Competitors RAPT Competitors SCYX Competitors BGM Competitors VTVT Competitors IMNN Competitors IMMX Competitors XLO Competitors VYNE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CSCI) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
